Nuvectis Pharma
NVCT
20.35
+0.06
+0.30%
Nuvectis Pharma
US · NVCT
#3557 by market cap
Listed 2022
20.35
+0.06
+0.30%
Live - 5344 symbols - heartbeat 317s ago
· 2026-10-08 09:55
After-hours
20.29
0.00%
- Market cap
- 664.31M
- P/E (TTM)i
- -15.42
- P/Bi
- 73.20
- EPSi
- -1.32
- Div yieldi
- 0.00%
- 52W posi
- 62%
Reader sentiment
Are you bullish or bearish on NVCT?
Anonymous reader poll. Unscientific, not investment advice.
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
- Founded
- 2020
- CEO
- Mr. Ron Bentsur
- Employees
- 13
- Headquarters
- Fort Lee, New Jersey, United States of America
- Fiscal year end
- 12-31
- Website
- nuvectis.com
Company profile
- Exchange
- US
- Symbol
- NVCT
- Market-cap rank
- #3557
- Listing date
- 2022-02-04
- Market cap
- 664.31M
- Float cap
- 432.76M
- Shares out
- 32.64M
- Float shares
- 21.27M
Sectors & themes
Quote time 2026-10-08 09:55:10 · For reference only, not investment advice and not tailored to your situation.